Protagonist Therapeutics (PTGX) Competitors

$105.15 +1.27 (+1.22%)

As of 02:34 PM Eastern

PTGX vs. BNTX, INSM, VTRS, ROIV, and MRNA

Should you buy Protagonist Therapeutics stock or one of its competitors? MarketBeat compares Protagonist Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Protagonist Therapeutics include BioNTech (BNTX), Insmed (INSM), Viatris (VTRS), Roivant Sciences (ROIV), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.

How does Protagonist Therapeutics compare to BioNTech?

Protagonist Therapeutics (NASDAQ:PTGX) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

In the previous week, Protagonist Therapeutics had 1 more articles in the media than BioNTech. MarketBeat recorded 14 mentions for Protagonist Therapeutics and 13 mentions for BioNTech. BioNTech's average media sentiment score of 0.58 beat Protagonist Therapeutics' score of 0.10 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Protagonist Therapeutics currently has a consensus target price of $113.69, indicating a potential upside of 8.13%. BioNTech has a consensus target price of $130.60, indicating a potential upside of 41.83%. Given BioNTech's higher probable upside, analysts plainly believe BioNTech is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
BioNTech	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

Protagonist Therapeutics has a beta of 1.89, suggesting that its share price is 89% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

Protagonist Therapeutics has higher earnings, but lower revenue than BioNTech. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	91.30	-$130.15M	-$1.81	N/A
BioNTech	$3.25B	7.17	-$1.29B	-$5.88	N/A

BioNTech has a net margin of -44.39% compared to Protagonist Therapeutics' net margin of -154.88%. BioNTech's return on equity of -5.30% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
BioNTech	-44.39%	-5.30%	-4.62%

Summary

BioNTech beats Protagonist Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Insmed?

Protagonist Therapeutics (NASDAQ:PTGX) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

Protagonist Therapeutics has a beta of 1.89, suggesting that its share price is 89% more volatile than the broader market. Comparatively, Insmed has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Protagonist Therapeutics has higher earnings, but lower revenue than Insmed. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	91.30	-$130.15M	-$1.81	N/A
Insmed	$606.42M	41.27	-$1.28B	-$5.75	N/A

In the previous week, Insmed had 25 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 39 mentions for Insmed and 14 mentions for Protagonist Therapeutics. Insmed's average media sentiment score of 0.56 beat Protagonist Therapeutics' score of 0.10 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	14 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

Protagonist Therapeutics currently has a consensus target price of $113.69, indicating a potential upside of 8.13%. Insmed has a consensus target price of $210.95, indicating a potential upside of 82.72%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Insmed has a net margin of -144.44% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Insmed	-144.44%	-130.11%	-51.57%

Summary

Insmed beats Protagonist Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Viatris?

Protagonist Therapeutics (NASDAQ:PTGX) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

Protagonist Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market. Comparatively, Viatris has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Protagonist Therapeutics has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	91.30	-$130.15M	-$1.81	N/A
Viatris	$14.30B	1.40	-$3.51B	-$0.26	N/A

In the previous week, Viatris had 3 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 17 mentions for Viatris and 14 mentions for Protagonist Therapeutics. Viatris' average media sentiment score of 0.64 beat Protagonist Therapeutics' score of 0.10 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viatris	2 Very Positive mention(s)	6 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics presently has a consensus target price of $113.69, suggesting a potential upside of 8.13%. Viatris has a consensus target price of $15.71, suggesting a potential downside of 8.46%. Given Protagonist Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protagonist Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Viatris has a net margin of -2.04% compared to Protagonist Therapeutics' net margin of -154.88%. Viatris' return on equity of 19.04% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Viatris	-2.04%	19.04%	7.62%

Summary

Protagonist Therapeutics beats Viatris on 9 of the 16 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Roivant Sciences?

Protagonist Therapeutics (NASDAQ:PTGX) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

Protagonist Therapeutics has a net margin of -154.88% compared to Roivant Sciences' net margin of -6,079.94%. Protagonist Therapeutics' return on equity of -17.76% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Roivant Sciences	-6,079.94%	-19.04%	-18.15%

Protagonist Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

Protagonist Therapeutics presently has a consensus target price of $113.69, suggesting a potential upside of 8.13%. Roivant Sciences has a consensus target price of $30.55, suggesting a potential upside of 3.75%. Given Protagonist Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protagonist Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 10.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Protagonist Therapeutics has higher revenue and earnings than Roivant Sciences. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	91.30	-$130.15M	-$1.81	N/A
Roivant Sciences	$29.05M	725.48	-$171.98M	-$1.17	N/A

In the previous week, Protagonist Therapeutics had 6 more articles in the media than Roivant Sciences. MarketBeat recorded 14 mentions for Protagonist Therapeutics and 8 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.76 beat Protagonist Therapeutics' score of 0.10 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Protagonist Therapeutics beats Roivant Sciences on 11 of the 16 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Moderna?

Moderna (NASDAQ:MRNA) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Moderna has a net margin of -143.55% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Moderna has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market.

Moderna presently has a consensus target price of $35.73, suggesting a potential downside of 28.64%. Protagonist Therapeutics has a consensus target price of $113.69, suggesting a potential upside of 8.13%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protagonist Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

75.3% of Moderna shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Protagonist Therapeutics has lower revenue, but higher earnings than Moderna. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	10.22	-$2.82B	-$8.15	N/A
Protagonist Therapeutics	$74.06M	91.30	-$130.15M	-$1.81	N/A

In the previous week, Moderna had 23 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 37 mentions for Moderna and 14 mentions for Protagonist Therapeutics. Moderna's average media sentiment score of 0.65 beat Protagonist Therapeutics' score of 0.10 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	19 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Protagonist Therapeutics beats Moderna on 10 of the 16 factors compared between the two stocks.

Get Protagonist Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTGX vs. The Competition

Export

Metric	Protagonist Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.75B	$3.40B	$6.29B	$12.48B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-57.99	18.81	20.91	25.60
Price / Sales	91.30	284.65	548.78	75.41
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	10.32	6.78	9.87	6.72
Net Income	-$130.15M	$24.11M	$3.55B	$333.73M
7 Day Performance	6.37%	0.22%	-0.24%	0.38%
1 Month Performance	0.41%	1.08%	1.44%	4.02%
1 Year Performance	140.23%	78.09%	41.01%	36.37%

Protagonist Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTGX Protagonist Therapeutics	1.7523 of 5 stars	$105.15 +1.2%	$113.69 +8.1%	+134.7%	$6.75B	$74.06M	N/A	120	Insider Trade
BNTX BioNTech	3.8392 of 5 stars	$94.13 +1.2%	$131.60 +39.8%	-2.4%	$23.52B	$3.25B	N/A	7,807	Analyst Forecast Buyback Announcement
INSM Insmed	3.1636 of 5 stars	$101.17 -3.6%	$211.86 +109.4%	+79.6%	$22.66B	$606.42M	N/A	1,664	Earnings Report Analyst Forecast Analyst Revision High Trading Volume
VTRS Viatris	2.5693 of 5 stars	$17.17 -1.3%	$15.71 -8.5%	+97.6%	$20.25B	$14.30B	N/A	30,000	Earnings Report
ROIV Roivant Sciences	2.3948 of 5 stars	$28.56 +1.0%	$30.55 +7.0%	+171.6%	$20.24B	$29.05M	N/A	860	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTGX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protagonist Therapeutics (PTGX) Competitors

PTGX vs. BNTX, INSM, VTRS, ROIV, and MRNA

How does Protagonist Therapeutics compare to BioNTech?

Summary

How does Protagonist Therapeutics compare to Insmed?

Summary

How does Protagonist Therapeutics compare to Viatris?

Summary

How does Protagonist Therapeutics compare to Roivant Sciences?

Summary

How does Protagonist Therapeutics compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTGX vs. The Competition

Protagonist Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protagonist Therapeutics (PTGX) Competitors

PTGX vs. BNTX, INSM, VTRS, ROIV, and MRNA

How does Protagonist Therapeutics compare to BioNTech?

Does the media prefer PTGX or BNTX?

Do insiders and institutionals have more ownership in PTGX or BNTX?

Do analysts rate PTGX or BNTX?

Which has more risk and volatility, PTGX or BNTX?

Which has stronger earnings and valuation, PTGX or BNTX?

Is PTGX or BNTX more profitable?

Summary

How does Protagonist Therapeutics compare to Insmed?

Which has more risk and volatility, PTGX or INSM?

Do insiders and institutionals have more ownership in PTGX or INSM?

Which has stronger earnings and valuation, PTGX or INSM?

Does the media prefer PTGX or INSM?

Do analysts rate PTGX or INSM?

Is PTGX or INSM more profitable?

Summary

How does Protagonist Therapeutics compare to Viatris?

Which has more volatility and risk, PTGX or VTRS?

Do institutionals and insiders have more ownership in PTGX or VTRS?

Which has stronger valuation and earnings, PTGX or VTRS?

Does the media favor PTGX or VTRS?

Do analysts prefer PTGX or VTRS?

Is PTGX or VTRS more profitable?

Summary

How does Protagonist Therapeutics compare to Roivant Sciences?

Is PTGX or ROIV more profitable?

Which has more volatility and risk, PTGX or ROIV?

Do analysts prefer PTGX or ROIV?

Do institutionals and insiders have more ownership in PTGX or ROIV?

Which has stronger valuation and earnings, PTGX or ROIV?

Does the media favor PTGX or ROIV?

Summary

How does Protagonist Therapeutics compare to Moderna?

Is MRNA or PTGX more profitable?

Which has more volatility & risk, MRNA or PTGX?

Do analysts prefer MRNA or PTGX?

Do insiders & institutionals have more ownership in MRNA or PTGX?

Which has higher valuation & earnings, MRNA or PTGX?

Does the media favor MRNA or PTGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTGX vs. The Competition

Protagonist Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools